DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

Information regarding the total number of voting rights and

total number of shares of the Company as of July 31, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
07/31/2024



 		96,498,927



 		 



Total gross of voting rights: 96,498,927



 
 



Total net* of voting rights: 96,214,457



 

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
02/08/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies clôture le screening des sujets de l'essai clinique d...

DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a dépassé son objectif de recrutement, clôturant avec succès au troisième trimestre 2024, le processus de sélection des sujets de l'étude de phase 3 VITESSE évaluant le patch Viaskin® Peanut chez les enfants allergiques à l'arachide âgés de 4 à 7 ansLes premiers résultats de l'étude VITESSE sont attendus pour le quatrième trimestre 2025. DBV Technologies (E...

September 23, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical ...

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 years oldTopline results of VITESSE data are expected by Q4 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announc...

September 23, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Glo...

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City. A live webcast ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and total num...

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights07/31/2024 96,498,927  Total gross of voting rights: 96,498,927  Total net* of voting rights: 96,214,457  * Net total = total number of voting rights attached to ...

August 2, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date  Nombre totald’actionscomposant le capital socialNombre totalde droits de vote31/07/2024 96 498 927  Total brut des droits de vote : 96 498 927  Total net* des droits de vote : 96 214 457  *Total net = nombre total ...

August 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch